Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (NASDAQ:REGN) on Wednesday, setting a price target of $570, which is approximately 17.48% above the present share price of $485.18.
Skorney expects Regeneron to post earnings per share (EPS) of $10.90 for the second quarter of 2021.
The current consensus among 13 TipRanks analysts is for a Moderate Buy rating of shares in Regeneron, with an average price target of $635.6.
The analysts price targets range from a high of $760 to a low of $477.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $2.42 billion and a net profit of $1.17 billion. The company's market cap is $51.68 billion.
According to TipRanks.com, Robert W. Baird analyst Brian Skorney is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.8% and a 49.40% success rate.
Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, manufactures, and commercializes medicines for the treatment of various medical conditions. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.